Search clinical trials for: PF-04449913%2C+ketoconazole

Total 32 results

Fred Hutchinson Cancer Center
Pfizer

Terminated

Glasdegib for Chronic Graft-Versus-Host Disease

Chronic Graft Versus Host Disease | Fasciitis

United States
Pfizer

Completed

A Study Of PF-04449913 Administered Alone In Select Solid Tumors

Solid Tumors

United States
Pfizer

Completed

A Study Of PF-04449913 In Select Hematologic Malignancies

Hematologic Malignancies

United States, Italy
Pfizer

Completed

A Study To Understand How Radiolabelled PF-04449913 Is Taken Up By The Body, Broken Down And Then Removed From The Body

Healthy

United States
Grupo Espanol de trasplantes hematopoyeticos y...

Active, not recruiting

Glasdegib in Refractory Patients With Sclerotic Chronic Graft-Versus-Host Disease

Sclerodermoid Chronic Graft-Versus-Host Disease (Disorder)

Spain
Pfizer

Terminated

Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

United States, Japan
University of Colorado, Denver
The Leukemia and Lymphoma Society

Completed

PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia in Remission

United States
Pfizer

Completed

A Study To Evaluate Whether Food Affects The Plasma Drug Levels Of A 35 mg Single Dose Of PF-04447943 Taken Orally In Healthy Adult Participants

Healthy

United States
Pfizer

Completed

A Study to Evaluate Safety, Tolerability, Plasma Drug Levels, and Cognitive Response Following Multiple Doses of a Drug in Healthy Elderly Participants.

Healthy | Elderly

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)

Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS)

United States
Pfizer

Completed

A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

United States, Canada, Chile, Czechia
Pfizer

Terminated

A Phase I, Multiple Dose Study of PF-04447943 in Healthy Elderly Volunteers

Healthy | Elderly

United States
Pfizer

Completed

A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Of PF-04447943 When Administered With Donepezil To Healthy Volunteer Subjects

Healthy

Singapore
Pfizer

Completed

Study To Determine The Effect Of Food And Strong CYP3A4 Enzyme Inhibitor On PF-04449913 Drug Levels

Healthy Volunteers

United States
Pfizer

Completed

A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Pfizer

Completed

Study Of Single Ascending And Multiple Doses Of PF-04447943 In Japanese Subjects.

Healthy

United States
Genzyme, a Sanofi Company

Active, not recruiting

Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension (LEAP)

Gaucher Disease Type 1 | Gaucher Disease Type 3

Germany, United States, Japan, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Pfizer

Completed

A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients (BRIGHT 1012)

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

United States, United Kingdom, Belgium, Canada, Germany, France
Pfizer

Completed

Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

Spain, Canada, Austria, Czechia, France, Hungary, Italy, Japan, Mexico, Poland, United Kingdom
Grupo Español de Investigación en Neurooncología

Completed

Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma (GEINOGLAS)

Glioblastoma

Spain
Pfizer

Completed

A Study To Estimate The Effect Of Ketoconazole On The Pharmacokinetics Of Pf-04937319 In Healthy Subjects

Human Volunteers

United States
Pfizer

Completed

A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects

Healthy

United States
Pfizer

Completed

A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia (BRIGHT AML1019)

Leukemia, Myeloid, Acute

United States, Spain, Canada, Israel, Korea, Republic of, Taiwan, France, Australia, Germany, Mexico, Japan, Sweden, China, Austria, Belgium, Czechia, Hungary, Italy, Poland, Romania, Russian Federation, United Kingdom
Pfizer

Completed

A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies

Acute Myeloid Leukemia

Japan
Pfizer

Completed

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia

United States, Spain, Germany, Italy, Poland, Canada
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Food Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Food Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg

Healthy

United States
Institut National de la Santé Et de la Recherche...
Institut Bergonié; Commissariat A L'energie Atomique; Plateforme labellisée Inca... and other collaborators

Active, not recruiting

Molecular Profiling of Advanced Soft-tissue Sarcomas (MULTISARC)

Soft Tissue Sarcoma

France
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation

Recurrent Acute Myeloid Leukemia

United States

3

Subscribe